Climb Bio: Meet The Newest Star in Autoimmune Disease Treatment – Initiation Report
Visit Exec Edge Research for Full Report By Rayk Riechmann As one of the brightest emerging biotechnology companies, Climb Bio Inc. (NASDAQ: CLYM) aims to improve the efficacy of autoimmune disease treatment. With its recently acquired lead asset, Budoprutug, and...